Clinical trials: Acute Myeloid Leukemia (AML) With
FLT3-mutated Acute Myeloid Leukemia
An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
The purpose of this study is to gather and evaluate additional safety data on the combination of midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute…
- Trial name
- NCT03114228
- Testing
- Midostaurin
- Where
- 2 sites in Canada
- Sponsor
- Novartis Pharmaceuticals
Adult Acute Myeloid Leukemia
Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML
Patients enrolled from each center according to confirmed criteria specified in cooperative scheme are recieved induction and consolidation chemotherapy with microtransplantation .
- Trial name
- NCT05262465
- Testing
- microtransplantation, HLA-mismatched donor peripheral stem cell infusion, Azacitidine, Venetoclax
- Where
- China
- Volunteers
- 300 people
- Sponsor
- guomei
Leukemia, Lymphoma
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about diagnosing cancer and determine a patient's eligibility for a treatment…
- Trial name
- NCT00897767
- Testing
- biologic sample preservation procedure
- Where
- 214 sites in United States
- Volunteers
- 1,873 people
- Sponsor
- Eastern Cooperative Oncology Group
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
This is a phase I/II pediatric dose-ranging study that will evaluate the safety, tolerability, clinical response, pharmacokinetics and pharmacodynamics of midostaurin in patients <18 years of age who have relapsed or refractory…
- Trial name
- NCT00866281
- Testing
- midostaurin
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Promyelocytic Leukemia (M3)
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
This phase I trial is studying the side effects and best dose of bortezomib in treating young patients with refractory or recurrent leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Promyelocytic Leukemia (M3), Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT00077467
- Testing
- bortezomib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies
The primary purpose of this study is to evaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies including refractory acute leukemia.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00270881
- Testing
- Cord blood transplantation, TBI, cyclophosphamide
- Where
- Japan
- Volunteers
- 33 people
- Sponsor
- Keio University
Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia
This laboratory study is looking into genes in samples from younger patients with acute megakaryoblastic leukemia (AMKL). Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help…
- Trial name
- NCT01642069
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.
- Trial name
- NCT06470841
- Testing
- CHG Combined With Venetoclax and Azacytidine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Navy General Hospital, Beijing
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Evaluate the safety and tolerability of AMG 427 in adult subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). Estimate the maximum tolerated dose (MTD) and / or a biologically optimal dose (eg, recommended phase…
- Trial name
- 20170528 (NCT03541369)
- Testing
- AMG 427
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 64 people
- Sponsor
- Amgen
Relapsed/Refractory Acute Myeloid Leukemia
Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML
Evaluate the safety and tolerability of AMG 553 in adult and adolescent subjects with FLT3-positive R/R AML. Determine the maximum tolerated cell dose (MTCD) or recommended phase 2 cell dose (RP2CD) of AMG 553.
- Trial name
- NCT03904069
- Testing
- AMG 553
- Where
- 3 sites in United States
- Sponsor
- Amgen
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Non-Hodgkin Lymphoma
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
The purpose of this first in human study is to assess safety, tolerability, Pharmacokinetic (PK) and preliminary clinical activity and to estimate the Maximum Tolerated Doses (MTD(s))/ Recommended Phase 2 Doses (RP2D(s)) of…
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Non-Hodgkin Lymphoma, Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT03755154
- Testing
- S65487- initial scheme, S65487 - alternative scheme
- Where
- 11 sites in Australia, France and 2 more
- Volunteers
- 60 people
- Sponsor
- Institut de Recherches Internationales Servier
Acute Myeloid Leukemia
NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia
The overall objective is to improve the cure rate of children with newly diagnosed acute myeloid leukemia (AML) who undergo risk-adapted therapy.
- Trial name
- NCT00476541
- Testing
- Gemtuzumab ozogamicin
- Where
- 2 sites in Denmark
- Volunteers
- 250 people
- Sponsor
- University of Aarhus
Acute Myeloid Leukemia
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
This phase I trial studies the side effects and best dose of ruxolitinib (Rux) therapy alone (monotherapy) followed by Rux plus azacitidine (AZA) maintenance therapy and to see how well it works in treating patients with acute…
- Trial name
- NCT07548983
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Myeloid Leukemia
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this research study is to determine if plerixafor can make cells more sensitive to killing by cytarabine and daunorubicin, an anti-cancer drug regimen referred to as "7+3" that is commonly used in treating acute…
- Trial name
- NCT00990054
- Testing
- Plerixafor
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Acute Myeloid Leukemia
Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
The main objective of the study is to improve outcome of younger patients (between 18-60 years) with acute myeloid leukemia and intermediate risk defined by the cytogenetics.
- Trial name
- LAM2006IR (NCT00860639)
- Testing
- gemtuzumab ozogamycin
- Where
- 29 sites in France
- Volunteers
- 327 people
- Sponsor
- Nantes University Hospital
Solid Tumor and Hematologic Malignancies
MEK162 for Patients With RAS/RAF/MEK Activated Tumors
The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT01885195)
- Testing
- MEK162
- Where
- 68 sites in United States
- Volunteers
- 110 people
- Sponsor
- Pfizer
Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
The purpose of this study is to assess the safety and tolerability of BMS-936564 (MDX-1338) in relapsed Acute myelogenous leukemia (AML) and other selected B-cell cancers and to determine the maximum tolerated dose (MTD) of the…
- Conditions
- Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma
- Trial name
- NCT01120457
- Testing
- BMS-936564 (Anti-CXCR4)
- Where
- 11 sites in United States
- Volunteers
- 96 people
- Sponsor
- Bristol-Myers Squibb
AML (Acute Myeloid Leukemia), BMI
Prognostic Impacts of Lipid Profile and BMI in Adult AML
The goal of this observational study is to evaluate the changes in lipid profile parameters (total cholesterol, triglycerides, HDL-C, and LDL-C) in adult AML patients before and after intensive induction chemotherapy.
- Conditions
- AML (Acute Myeloid Leukemia), BMI, Lipid Profile, Induction Chemotherapy
- Trial name
- AML/BMI (NCT07143877)
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Assiut University
Leukemia
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
This phase II trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute…
- Trial name
- NCT01009931
- Testing
- 12-O-tetradecanoylphorbol-13-acetate, Dexamethasone, Choline magnesium trisalicylate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rutgers, The State University of New Jersey
Chronic Myeloproliferative Disorders, Leukemia
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of decitabine and FR901228 in treating patients with relapsed or refractory leukemia, myelodysplastic syndromes or myeloproliferative disorders.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00114257
- Testing
- decitabine, romidepsin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.